Atropine Sulfate
RxNorm 1190570· ATROPINE SULFATE· OPHTHALMIC
Bausch & Lomb Incorporated
Indications and usage
INDICATIONS AND USAGE For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract.
Dosage and administration
DOSAGE AND ADMINISTRATION Apply a small amount of ointment to the conjunctival sac once or twice a day, or as directed by a physician. FOR OPHTHALMIC USE ONLY
Warnings
WARNINGS In pediatric patients, use with extreme caution. Excessive use in pediatric patients or in certain individuals with a previous history of susceptibility to belladonna alkaloids may produce systemic symptoms of atropine poisoning. If this occurs, discontinue medication and use appropriate therapy as outlined in OVERDOSAGE .
Contraindications
CONTRAINDICATIONS This product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma. This product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. This product should not be used in those persons showing hypersensitivity to any component of this preparation.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- diarrhoea3,449
- nausea2,281
- fatigue2,026
- drug ineffective1,997
- off label use1,484
- death1,458
- vomiting1,422
- pain1,318
- dyspnoea1,195
- weight decreased1,097
- abdominal pain1,046
- asthenia1,040
- headache1,019
- pyrexia991
- dehydration945
- hypotension901
Adverse reactions (label)
ADVERSE REACTIONS Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by hypotension with progressive respiratory depression. Coma and death have been reported in the very young. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
View more: Full FDA label on DailyMed →Label effective 20200402